See more : Litium AB (publ) (LITI.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Gemini Therapeutics, Inc. (GMTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gemini Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fiberhome Telecommunication Technologies Co., Ltd. (600498.SS) Income Statement Analysis – Financial Results
- TransCanna Holdings Inc. (TCNAF) Income Statement Analysis – Financial Results
- Federal-Mogul Goetze (India) Limited (FMGOETZE.BO) Income Statement Analysis – Financial Results
- Mytrex Health Technologies, Inc. (4431.TWO) Income Statement Analysis – Financial Results
- Grupo Financiero Inbursa, S.A.B. de C.V. (4FY.F) Income Statement Analysis – Financial Results
Gemini Therapeutics, Inc. (GMTX)
About Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Unable to fetch income statement for: GMTX
7 Short-Squeeze Stocks for Bold Contrarians to Consider
Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's version of playing chicken.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY
NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Gemini Therapeutics,...
GEMINI THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. – GMTX
NEW ORLEANS, Sept. 21, 2022 /PRNewswire/ — Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Gemini Therapeutics, Inc. (NasdaqGM: GMTX) with...
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ
NEW YORK , Aug. 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Gemini Therapeutics,...
Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Gemini Therapeutics, Inc. (GMTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the...
Gemini Therapeutics Shares Jump As HC Wainwright Sees Over 500% Upside
H.C. Wainwright initiated coverage of Gemini Therapeutics Inc (NASDAQ: GMTX) with a Buy rating and $20 price target. In the near term, the expected Phase 2a readout for lead asset GEM103 can serve as a platform catalyst, analyst Matthew Caufield tells investors in a...
Gemini Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in...
Should You Buy Gemini Therapeutics (GMTX) Ahead of Earnings?
Gemini Therapeutics (GMTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GMTX Stock: Why It Fell This Week
The stock price of Gemini Therapeutics Inc (NASDAQ: GMTX) fell over 10% this week. This is why it happened.
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced one oral presentation and the presentation of three posters at the 13th International Conference on...
Source: https://incomestatements.info
Category: Stock Reports